T 0001/18 (EML4-ALK INHIBITORS FOR TREATING NSCLC / NOVARTIS) of 28.09.2021
- European Case Law Identifier
- ECLI:EP:BA:2021:T000118.20210928
- Date of decision
- 28 September 2021
- Case number
- T 0001/18
- Petition for review of
- -
- Application number
- 12703670.5
- Language of proceedings
- English
- Distribution
- No distribution (D)
- Download
- Decision in English
- OJ versions
- No OJ links found
- Other decisions for this case
- -
- Abstracts for this decision
- -
- Application title
- METHODS OF USING ALK INHIBITORS
- Applicant name
- Novartis AG
- Opponent name
- Teva Pharmaceutical Industries Ltd
Generics [UK] Limited
I P S Intellectual Property Services - Board
- 3.3.02
- Headnote
- -
- Relevant legal provisions
- European Patent Convention Art 104(1)European Patent Convention Art 56
- Keywords
- Inventive step - (yes)
Different apportionment of costs - (no) - Catchword
- -
- Cited cases
- T 0013/19
- Citing cases
- -
Order
For these reasons it is decided that:
1. The appeals are dismissed.
2. The request for a different apportionment of costs is rejected.